Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single Arm, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 Plus Vemurafenib in Patients With BRAF V600 Mutant Advanced Solid Tumor

NCT03781219 is registered in ClinicalTrials.gov with Shanghai Kechow Pharma, Inc. as lead sponsor.

NCT NCT03781219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03781219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single Arm, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 Plus Vemurafenib in Patients With BRAF V600 Mutant Advanced Solid Tumor
Lead sponsor
Shanghai Kechow Pharma, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
July 1, 2018
Completion date
December 1, 2023
Enrollment
45 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor